|
"hamilton e"的相關文件
顯示項目 1-4 / 4 (共1頁)
1
每頁顯示[10|25|50]項目
| 國立成功大學 |
2023 |
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|
Hurvitz, S.A.;Hegg, R.;Chung, W.-P.;Im, S.-A.;Jacot, W.;Ganju, V.;Chiu, J.W.Y.;Xu, B.;Hamilton, E.;Madhusudan, S.;Iwata, H.;Altintas, S.;Henning, J.-W.;Curigliano, G.;Perez-Garcia, J.M.;Kim, S.-B.;Petry, V.;Huang, C.-S.;Li, W.;Frenel, J.-S.;Antolin, S.;Yeo, W.;Bianchini, G.;Loi, S.;Tsurutani, J.;Egorov, A.;Liu, Y.;Cathcart, J.;Ashfaque, S.;Cort�s, J. |
| 臺大學術典藏 |
2022-04-15T02:42:33Z |
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
|
Harbeck, N; Rastogi, P; Martin, M; Tolaney, S M; Shao, Z M; Fasching, P A; CHIUN-SHENG HUANG; Jaliffe, G G; Tryakin, A; Goetz, M P; Rugo, H S; Senkus, E; Testa, L; Andersson, M; Tamura, K; Del Mastro, L; Steger, G G; Kreipe, H; Hegg, R; Sohn, J; Guarneri, V; Cortés, J; Hamilton, E; André, V; Wei, R; Barriga, S; Sherwood, S; Forrester, T; Munoz, M; Shahir, A; San Antonio, B; Nabinger, S C; Toi, M; Johnston, S R D; O'Shaughnessy, J |
| 國立成功大學 |
2022 |
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
|
Cort�s, J.;Kim, S.-B.;Chung, W.-P.;Im, S.-A.;Park, Y.H.;Hegg, R.;Kim, M.H.;Tseng, L.-M.;Petry, V.;Chung, Chung C.-F.;Iwata, H.;Hamilton, E.;Curigliano, G.;Xu, B.;Huang, C.-S.;Kim, J.H.;Chiu, J.W.Y.;Pedrini, J.L.;Lee, C.;Liu, Y.;Cathcart, J.;Bako, E.;Verma, S.;Hurvitz, S.A.;Investigators, DESTINY-Breast03 Trial |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer
|
Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. |
顯示項目 1-4 / 4 (共1頁)
1
每頁顯示[10|25|50]項目
|
